First patient recruited for Donesta® Phase III Clinical Study in Europe

  • Recruitment of the first patient for the second pivotal Donesta® Phase III study conducted in 12 countries in Europe, Russia and South America
  • “E4 Comfort” Phase III Clinical Program for Donesta® successfully launched in October 2019 with recruitment of first patient for North American study
  • Phase III Program aimed at enrolling approximately 2200 menopausal women with vasomotor symptoms
Liege, Belgium, 31 December 2019 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the recruitment of the first patient for the second pivotal Phase III Donesta® clinical study. Donesta® is a next generation orally-administered E4-based hormone therapy product candidate for the relief of menopausal vasomotor symptoms (VMS).